Table 2.

A brief summary of large randomised clinical trials actively recruiting patients for CP treatment in COVID-19

Sponsor	Participants	Population	Control	Primary outcome
Cristina AvendañoSo (Con-Plas 19 trial)	278	Hospitalized patients without mechanical ventilation	Hospitalized with standard of care treatment	Category changes in ordinal scale—proportion of patients in categories 5,6 or 7 of the 7-point ordinal scale at day 15.
Erasmus Medical Center(CoV-Early Trial)	690	300 ml CP with a minimum of neutralising antibodies	300 ml fresh frozen plasma	Highest disease status on the 5-point ordinal disease severity scale in the CP group will be compared with the FFP group.
Institute of Liver and Biliary Sciences, India	400	Two doses of CP + standard of care to severely sick COVID-19 patients	Standard of care treatment	Efficacy of CP in time to clinical improvement (clinical improvement: reduction of two points in ordinal scale or live discharge from the intensive care unit, whichever is earlier) (time frame: day 28)
Johns Hopkins University	150	Asymptomatic, with negative PCR test and high-risk exposure and higher risk for severe illness	Asymptomatic high-risk control treated with standard plasma	1. Death 2. Requiring mechanical ventilation and/or in ICU 3. Non-ICU hospitalization, requiring supplemental oxygen 4. Non-ICU hospitalization, not requiring supplemental oxygen 5. Not hospitalized, but with clinical and laboratory evidence of COVID-19 infection 6. Not hospitalized, no clinical evidence of COVID-19 infection, but positive PCR for SARS-CoV-2